Findings

What do systematic reviews say?

3 questions · 3 findings · 2 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 2 · 66.7%Moderate 1 · 33.3%High 0 · 0%

Intermittent ICS vs placebo

Serious adverse events · School‐aged children and adults

Intermittent ICS showed no clear difference in serious adverse events compared with placebo (moderate certainty).

1 finding from 1 review

Intermittent inhaled corticosteroid therapy versus placebo for persistent asthma in children and adults 2015 · Cochrane Headline outcomes only
OR 1 [0.14, 7.25]
2 studies · 385 participants
Moderate

Intermittent ICS vs placebo

Serious adverse events · Preschool children (<6 years)

Intermittent ICS showed no clear difference in serious adverse events compared with placebo (low certainty).

1 finding from 1 review

Intermittent inhaled corticosteroid therapy versus placebo for persistent asthma in children and adults 2015 · Cochrane Headline outcomes only
OR 0.42 [0.17, 1.02]
3 studies · 439 participants
Low

Intermittent 'as needed' ICS vs daily ICS

Patients with serious adverse health events (duration 12 to 52 weeks) · Children and adults with persistent asthma.

Intermittent 'as needed' ICS showed no clear difference in patients with serious adverse health events (duration 12 to 52 weeks) compared with daily ICS (low certainty).

1 finding from 1 review

Intermittent versus daily inhaled corticosteroids for persistent asthma in children and adults 2013 · Cochrane Headline outcomes only
RR 0.82 [0.33, 2.03]
6 studies · 1055 participants
Low